Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease

Experimental Neurology

Volumn 241, Issue 1, 2013, Pages 148-155

  Pradhan, Suraj ^a   Andreasson, Katrin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

synuclein; Inflammation; Microglia; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CD4 ANTIGEN; CD8 ANTIGEN; DOPAMINE; GAMMA INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOPATHOLOGY; LEWY BODY; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NOTE; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SUBSTANTIA NIGRA; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE-ENVIRONMENT INTERACTION; HUMANS; INFLAMMATION; LEWY BODIES; MICE; MICROGLIA; NEUROTOXICITY SYNDROMES; PARKINSON DISEASE;

EID: 84872770499     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.12.008     Document Type: Note

References (160)

1. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., Grandinetti A., Blanchette P.L., Popper J.S., Ross G.W. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57:456-462.
2. Ahmed I., Tamouza R., Delord M., Krishnamoorthy R., Tzourio C., Mulot C., Nacfer M., Lambert J.C., Beaune P., Laurent-Puig P., Loriot M.A., Charron D., Elbaz A. Association between Parkinson's disease and the HLA-DRB1 locus. Mov. Disord. 2012, 27:1104-1110.
3. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 1997, 69:1326-1329.
4. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 1997, 69:1196-1203.
5. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., Shen X., Chataway T., Schlossmacher M.G., Seubert P., Schenk D., Sinha S., Gai W.P., Chilcote T.J. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
6. Angot E., Steiner J.A., Hansen C., Li J.Y., Brundin P. Are synucleinopathies prion-like disorders?. Lancet Neurol. 2010, 9:1128-1138.
7. Attems J., Jellinger K.A. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Neuropathol. Appl. Neurobiol. 2008, 34:466-467.
8. Barnum C.J., Tansey M.G. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?. Curr. Neurol. Neurosci. Rep. 2012, 12:350-358.
9. Bas J., Calopa M., Mestre M., Mollevi D.G., Cutillas B., Ambrosio S., Buendia E. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J. Neuroimmunol. 2001, 113:146-152.
10. Beach T.G., Adler C.H., Sue L.I., Vedders L., Lue L., White Iii C.L., Akiyama H., Caviness J.N., Shill H.A., Sabbagh M.N., Walker D.G. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119:689-702.
11. Becker C., Jick S.S., Meier C.R. NSAID use and risk of Parkinson disease: a population-based case-control study. Eur. J. Neurol. 2011, 18:1336-1342.
12. Beraud D., Twomey M., Bloom B., Mittereder A., Ton V., Neitzke K., Chasovskikh S., Mhyre T.R., Maguire-Zeiss K.A. alpha-synuclein alters Toll-like receptor expression. Front. Neurosci. 2011, 5:80.
13. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
14. Beyer K., Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol. Neurobiol. 2012, (Epub ahead of print) (PMID 22923347).
15. Bialecka M., Klodowska-Duda G., Kurzawski M., Slawek J., Gorzkowska A., Opala G., Bialecki P., Sagan L., Drozdzik M. Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients. Parkinsonism Relat. Disord. 2008, 14:636-640.
16. Blunt S.B., Lane R.J., Turjanski N., Perkin G.D. Clinical features and management of two cases of encephalitis lethargica. Mov. Disord. 1997, 12:354-359.
17. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 1994, 172:151-154.
18. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 2000, 287:65-67.
19. Bove J., Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012, 211:51-76.
20. Bower J.H., Maraganore D.M., Peterson B.J., McDonnell S.K., Ahlskog J.E., Rocca W.A. Head trauma preceding PD: a case-control study. Neurology 2003, 60:1610-1615.
21. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
22. Braak H., Rub U., Gai W.P., Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural. Transm. Park Dis. Dement Sect. 2003, 110:517-536.
23. Braak H., de Vos R.A., Bohl J., Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 2006, 396:67-72.
24. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.M., Duyckaerts C., Flavell R.A., Hirsch E.C., Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
25. Brodacki B., Staszewski J., Toczylowska B., Kozlowska E., Drela N., Chalimoniuk M., Stepien A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 2008, 441:158-162.
26. Brose N., O'Connor V., Skehel P. Synaptopathy: dysfunction of synaptic function?. Biochem. Soc. Trans. 2010, 38:443-444.
27. Brown T.P., Rumsby P.C., Capleton A.C., Rushton L., Levy L.S. Pesticides and Parkinson's disease-is there a link?. Environ. Health Perspect. 2006, 114:156-164.
28. Burke R.E., O'Malley K. Axon degeneration in Parkinson's disease. Exp. Neurol. 2012, (Epub ahead of print) (PMIC 22285449).
29. Burke R.E., Dauer W.T., Vonsattel J.P. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann. Neurol. 2008, 64:485-491.
30. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:4546-4550.
31. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Sudhof T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
32. Cabeza-Arvelaiz Y., Fleming S.M., Richter F., Masliah E., Chesselet M.F., Schiestl R.H. Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol. Neurodegener. 2011, 6:83.
33. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
34. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
35. Chen L., Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8:657-663.
36. Cheng H.C., Burke R.E. The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo. J. Neurochem. 2010, 113:683-691.
37. Cheng H.C., Ulane C.M., Burke R.E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 2010, 67:715-725.
38. Chesselet M.F., Richter F., Zhu C., Magen I., Watson M.B., Subramaniam S.R. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 2012, 9:297-314.
39. Chu Y., Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. Neurobiol. Dis. 2007, 25:134-149.
40. Colton C.A. Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 2009, 4:399-418.
41. Croisier E., Moran L.B., Dexter D.T., Pearce R.K., Graeber M.B. Microglial inflammation in the Parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J. Neuroinflammation 2005, 2:14.
42. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
43. Dawson T.M., Ko H.S., Dawson V.L. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
44. DelleDonne A., Klos K.J., Fujishiro H., Ahmed Z., Parisi J.E., Josephs K.A., Frigerio R., Burnett M., Wszolek Z.K., Uitti R.J., Ahlskog J.E., Dickson D.W. Incidental Lewy body disease and preclinical Parkinson disease. Arch. Neurol. 2008, 65:1074-1080.
45. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13010-13015.
46. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 1994, 9:92-97.
47. Dickson D.W., Fujishiro H., DelleDonne A., Menke J., Ahmed Z., Klos K.J., Josephs K.A., Frigerio R., Burnett M., Parisi J.E., Ahlskog J.E. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008, 115:437-444.
48. Dickson D.W., Fujishiro H., Orr C., DelleDonne A., Josephs K.A., Frigerio R., Burnett M., Parisi J.E., Klos K.J., Ahlskog J.E. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S1-S5.
49. Dobbs R.J., Charlett A., Purkiss A.G., Dobbs S.M., Weller C., Peterson D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 1999, 100:34-41.
50. Doty R.L. Olfaction in Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13(Suppl. 3):S225-S228.
51. Dourmashkin R.R. What caused the 1918-30 epidemic of encephalitis lethargica?. J. R. Soc. Med. 1997, 90:515-520.
52. Driver J.A., Logroscino G., Lu L., Gaziano J.M., Kurth T. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ 2011, 342:d198.
53. Drolet R.E., Cannon J.R., Montero L., Greenamyre J.T. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol. Dis. 2009, 36:96-102.
54. El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M., Ikeda S., Cookson M.R., Hardy J., Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003, 17:1945-1947.
55. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 1992, 32:804-812.
56. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 2001, 10:1847-1851.
57. Fellner L., Jellinger K.A., Wenning G.K., Stefanova N. Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol. 2011, 121:675-693.
58. Fernagut P.O., Chesselet M.F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 2004, 17:123-130.
59. Ferrer I., Martinez A., Blanco R., Dalfo E., Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J. Neural. Transm. Park. Dis. Dement Sect. 2011, 118:821-839.
60. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004, 185:232-240.
61. Fiszer U., Mix E., Fredrikson S., Kostulas V., Olsson T., Link H. gamma delta+ T cells are increased in patients with Parkinson's disease. J. Neurol. Sci. 1994, 121:39-45.
62. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 2004, 24:9434-9440.
63. Fleming S.M., Salcedo J., Hutson C.B., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 2006, 142:1245-1253.
64. Fleming S.M., Tetreault N.A., Mulligan C.K., Hutson C.B., Masliah E., Chesselet M.F. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 2008, 28:247-256.
65. Forsyth C.B., Shannon K.M., Kordower J.H., Voigt R.M., Shaikh M., Jaglin J.A., Estes J.D., Dodiya H.B., Keshavarzian A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011, 6:e28032.
66. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., Hartley M., Trevino I., O'Brien D.E., Casey B., Goldberg M.S., Tansey M.G. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 2008, 28:10825-10834.
67. Frigerio R., Fujishiro H., Ahn T.B., Josephs K.A., Maraganore D.M., DelleDonne A., Parisi J.E., Klos K.J., Boeve B.F., Dickson D.W., Ahlskog J.E. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?. Neurobiol. Aging 2011, 32:857-863.
68. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
69. Gaenslen A., Swid I., Liepelt-Scarfone I., Godau J., Berg D. The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. Mov. Disord. 2011, 26:653-658.
70. Gagne J.J., Power M.C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010, 74:995-1002.
71. Gao H.M., Liu B., Zhang W., Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 2003, 17:1957-1959.
72. Gao X., Chen H., Schwarzschild M.A., Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011, 76:863-869.
73. Gay D., Maddon P., Sekaly R., Talle M.A., Godfrey M., Long E., Goldstein G., Chess L., Axel R., Kappler J., et al. Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature 1987, 328:626-629.
74. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
75. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
76. Goldman S.M., Tanner C.M., Oakes D., Bhudhikanok G.S., Gupta A., Langston J.W. Head injury and Parkinson's disease risk in twins. Ann. Neurol. 2006, 60:65-72.
77. Greene J.G., Noorian A.R., Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp. Neurol. 2009, 218:154-161.
78. Hakimi M., Selvanantham T., Swinton E., Padmore R.F., Tong Y., Kabbach G., Venderova K., Girardin S.E., Bulman D.E., Scherzer C.R., LaVoie M.J., Gris D., Park D.S., Angel J.B., Shen J., Philpott D.J., Schlossmacher M.G. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J. Neural. Transm. Park. Dis. Dement. Sect. 2011, 118:795-808.
79. Hamza T.H., Zabetian C.P., Tenesa A., Laederach A., Montimurro J., Yearout D., Kay D.M., Doheny K.F., Paschall J., Pugh E., Kusel V.I., Collura R., Roberts J., Griffith A., Samii A., Scott W.K., Nutt J., Factor S.A., Payami H. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42:781-785.
80. Hansen C., Angot E., Bergstrom A.L., Steiner J.A., Pieri L., Paul G., Outeiro T.F., Melki R., Kallunki P., Fog K., Li J.Y., Brundin P. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
81. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 1999, 10:717-721.
82. Hawkes C.H., Del Tredici K., Braak H. A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 2010, 16:79-84.
83. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
84. Hisanaga K., Asagi M., Itoyama Y., Iwasaki Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch. Neurol. 2001, 58:1580-1583.
85. Hodara R., Norris E.H., Giasson B.I., Mishizen-Eberz A.J., Lynch D.R., Lee V.M., Ischiropoulos H. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 2004, 279:47746-47753.
86. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996, 72:355-363.
87. Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
88. Jang H., Boltz D., Sturm-Ramirez K., Shepherd K.R., Jiao Y., Webster R., Smeyne R.J. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14063-14068.
89. Jang H., Boltz D.A., Webster R.G., Smeyne R.J. Viral parkinsonism. Biochim. Biophys. Acta 2009, 1792:714-721.
90. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998, 44:S72-S84.
91. Kalaitzakis M.E., Graeber M.B., Gentleman S.M., Pearce R.K. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol. Appl. Neurobiol. 2008, 34:284-295.
92. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11441-11446.
93. Klegeris A., Pelech S., Giasson B.I., Maguire J., Zhang H., McGeer E.G., McGeer P.L. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 2008, 29:739-752.
94. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation 2008, 5:8.
95. Lam H.A., Wu N., Cely I., Kelly R.L., Hean S., Richter F., Magen I., Cepeda C., Ackerson L.C., Walwyn W., Masliah E., Chesselet M.F., Levine M.S., Maidment N.T. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J. Neurosci. Res. 2011, 89:1091-1102.
96. Lange K.W., Youdim M.B., Riederer P. Neurotoxicity and neuroprotection in Parkinson's disease. J. Neural. Transm. 1992, 38:27-44. (Supplementum).
97. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
98. Laurie C., Reynolds A., Coskun O., Bowman E., Gendelman H.E., Mosley R.L. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 2007, 183:60-68.
99. Lee S.J. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J. Mol. Neurosci. 2008, 34:17-22.
100. Lee H.J., Patel S., Lee S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci 2005, 25:6016-6024.
101. Lema Tome C.M., Tyson T., Rey N.L., Grathwohl S., Britschgi M., Brundin P. Inflammation and alpha-Synuclein's Prion-like behavior in Parkinson's disease - is there a link?. Mol. Neurobiol. 2012.
102. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
103. Ling Z.D., Chang Q., Lipton J.W., Tong C.W., Landers T.M., Carvey P.M. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004, 124:619-628.
104. Liu Z., Lee J., Krummey S., Lu W., Cai H., Lenardo M.J. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011, 12:1063-1070.
105. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog. Neurobiol. 2009, 89:277-287.
106. Lopez-Alberola R., Georgiou M., Sfakianakis G.N., Singer C., Papapetropoulos S. Contemporary Encephalitis Lethargica: phenotype, laboratory findings and treatment outcomes. J. Neurol. 2009, 256:396-404.
107. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 2002, 3:932-942.
108. Lucin K.M., Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122.
109. Magen I., Fleming S.M., Zhu C., Garcia E.C., Cardiff K.M., Dinh D., De La Rosa K., Sanchez M., Torres E.R., Masliah E., Jentsch J.D., Chesselet M.F. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur. J. Neurosci. 2012, 35:870-882.
110. Marinova-Mutafchieva L., Sadeghian M., Broom L., Davis J.B., Medhurst A.D., Dexter D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J. Neurochem. 2009, 110:966-975.
111. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
112. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Bienfait K., Dicke A., Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479.
113. Miklossy J., Doudet D.D., Schwab C., Yu S., McGeer E.G., McGeer P.L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 2006, 197:275-283.
114. Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M.R., Singleton A.B. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004, 62:1835-1838.
115. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180:147-150.
116. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
117. Mosley R.L., Hutter-Saunders J.A., Stone D.K., Gendelman H.E. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a009381.
118. Mount M.P., Lira A., Grimes D., Smith P.D., Faucher S., Slack R., Anisman H., Hayley S., Park D.S. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 2007, 27:3328-3337.
119. Nielsen H.H., Qiu J., Friis S., Wermuth L., Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur. J. Neurol. 2012, 19:864-869.
120. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173:3916-3924.
121. Orr C.F., Rowe D.B., Mizuno Y., Mori H., Halliday G.M. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128:2665-2674.
122. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57:168-175.
123. Ouchi Y., Yagi S., Yokokura M., Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S200-S204.
124. Pals P., Lincoln S., Manning J., Heckman M., Skipper L., Hulihan M., Van den Broeck M., De Pooter T., Cras P., Crook J., Van Broeckhoven C., Farrer M.J. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 2004, 56:591-595.
125. Pan-Montojo F., Anichtchik O., Dening Y., Knels L., Pursche S., Jung R., Jackson S., Gille G., Spillantini M.G., Reichmann H., Funk R.H. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010, 5:e8762.
126. Phani S., Loike J.D., Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S207-S209.
127. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
128. Postuma R.B., Aarsland D., Barone P., Burn D.J., Hawkes C.H., Oertel W., Ziemssen T. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov. Disord. 2012, 27:617-626.
129. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol. Dis. 2007, 25:392-400.
130. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27:119-145.
131. Rees K., Stowe R., Patel S., Ives N., Breen K., Clarke C.E., Ben-Shlomo Y. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst. Rev. 2011, CD008454.
132. Reid A.H., McCall S., Henry J.M., Taubenberger J.K. Experimenting on the past: the enigma of von Economo's encephalitis lethargica. J. Neuropathol. Exp. Neurol. 2001, 60:663-670.
133. Reynolds A.D., Glanzer J.G., Kadiu I., Ricardo-Dukelow M., Chaudhuri A., Ciborowski P., Cerny R., Gelman B., Thomas M.P., Mosley R.L., Gendelman H.E. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 2008, 104:1504-1525.
134. Reynolds A.D., Stone D.K., Mosley R.L., Gendelman H.E. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J. Immunol. 2009, 182:4137-4149.
135. Rockenstein E., Mallory M., Hashimoto M., Song D., Shults C.W., Lang I., Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 2002, 68:568-578.
136. Samii A., Etminan M., Wiens M.O., Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009, 26:769-779.
137. Savica R., Rocca W.A., Ahlskog J.E. When does Parkinson disease start?. Arch. Neurol. 2010, 67:798-801.
138. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
139. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
140. Sherer T.B., Betarbet R., Kim J.H., Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 2003, 341:87-90.
141. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
142. Sossi V., de la Fuente-Fernandez R., Nandhagopal R., Schulzer M., McKenzie J., Ruth T.J., Aasly J.O., Farrer M.J., Wszolek Z.K., Stoessl J.A. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov. Disord. 2010, 25:2717-2723.
143. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
144. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 2008, 29:1690-1701.
145. Su X., Federoff H.J., Maguire-Zeiss K.A. Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox. Res. 2009, 16:238-254.
146. Sugeno N., Takeda A., Hasegawa T., Kobayashi M., Kikuchi A., Mori F., Wakabayashi K., Itoyama Y. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J. Biol. Chem. 2008, 283:23179-23188.
147. Thevenet J., Pescini Gobert R., Hooft van Huijsduijnen R., Wiessner C., Sagot Y.J. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 2011, 6:e21519.
148. Thiruchelvam M.J., Powers J.M., Cory-Slechta D.A., Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur. J. Neurosci. 2004, 19:845-854.
149. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 1968, 5:107-110.
150. van der Mark M., Brouwer M., Kromhout H., Nijssen P., Huss A., Vermeulen R. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ. Health Perspect. 2012, 120:340-347.
151. Villaran R.F., Espinosa-Oliva A.M., Sarmiento M., De Pablos R.M., Arguelles S., Delgado-Cortes M.J., Sobrino V., Van Rooijen N., Venero J.L., Herrera A.J., Cano J., Machado A. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J. Neurochem. 2010, 114:1687-1700.
152. Vroon A., Drukarch B., Bol J.G., Cras P., Breve J.J., Allan S.M., Relton J.K., Hoogland P.V., Van Dam A.M. Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp. Gerontol. 2007, 42:762-771.
153. Wahner A.D., Sinsheimer J.S., Bronstein J.M., Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch. Neurol. 2007, 64:836-840.
154. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 2008, 29:574-585.
155. Wang L., Fleming S.M., Chesselet M.F., Tache Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. NeuroReport 2008, 19:873-876.
156. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
157. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6145-6150.
158. Wu N., Joshi P.R., Cepeda C., Masliah E., Levine M.S. Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J. Neurosci. Res. 2010, 88:1764-1776.
159. Yamada T., McGeer P.L., McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. 1992, 84:100-104.
160. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhou Y., Hong J.S., Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542.